209 related articles for article (PubMed ID: 34328006)
1. Complete resolution of chylothorax with ibrutinib in chronic lymphocytic leukemia: a case report.
Cheng L; Huang M; Wei J; Xu H; Zhou M; Jiang L
Ann Palliat Med; 2022 May; 11(5):1833-1837. PubMed ID: 34328006
[TBL] [Abstract][Full Text] [Related]
2. Complete resolution of chylopericardium after chemotherapy for chronic lymphocytic leukemia.
Morris AL; Colbourne T; Kirkpatrick I; Banerji V
Curr Oncol; 2019 Oct; 26(5):e696-e699. PubMed ID: 31708663
[TBL] [Abstract][Full Text] [Related]
3. Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities.
Aslan Candır B; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F
J Oncol Pharm Pract; 2022 Jun; 28(4):972-974. PubMed ID: 35006020
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation.
Yang S; Zhu R; Li N; Feng Y; Zuo R; Gale RP; Huang X
Acta Haematol; 2022; 145(1):54-62. PubMed ID: 34569486
[TBL] [Abstract][Full Text] [Related]
5. Chylous effusion complicating chronic lymphocytic leukemia.
Ampil FL; Burton GV; Hardjasudarma M; Stogner SW
Leuk Lymphoma; 1993 Aug; 10(6):507-10. PubMed ID: 8401188
[TBL] [Abstract][Full Text] [Related]
6. Use of Fludarabine for the Treatment of Indolent Lymphoma with Chylothorax.
Wild A; Holasová J; Králiková E
Klin Onkol; 2018; 31(4):301-304. PubMed ID: 30541315
[TBL] [Abstract][Full Text] [Related]
7. Chylothorax Associated with Chronic Lymphocytic Leukemia.
Kohmoto O; Kawabe K; Ono H; Yanagimoto R; Arimoto J; Hatada A; Suruda T; Minakata Y
Intern Med; 2016; 55(24):3641-3644. PubMed ID: 27980266
[TBL] [Abstract][Full Text] [Related]
8. Chylothorax in chronic lymphocytic leukemia patient.
Doerr CH; Staats BA; Markovic SN
Am J Hematol; 2002 Jul; 70(3):237-40. PubMed ID: 12111770
[TBL] [Abstract][Full Text] [Related]
9. Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis.
Ronconi G; Dondi L; Calabria S; Piccinni C; Pedrini A; Esposito I; Martini N
Clin Drug Investig; 2021 Jul; 41(7):595-604. PubMed ID: 34032988
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Jain N; Thompson P; Burger J; Ferrajoli A; Takahashi K; Estrov Z; Borthakur G; Bose P; Kadia T; Pemmaraju N; Sasaki K; Konopleva M; Jabbour E; Garg N; Wang X; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang S; Lopez W; Ayala A; Plunkett W; Gandhi V; Kantarjian H; O'Brien S; Keating M; Wierda WG
Leukemia; 2021 Dec; 35(12):3421-3429. PubMed ID: 34007049
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia.
Huntington SF; de Nigris E; Puckett J; Kamal-Bahl S; Farooqui M; Ryland K; Sarpong E; Leng S; Yang X; Doshi JA
Leuk Lymphoma; 2023 Dec; 64(14):2286-2295. PubMed ID: 37870435
[TBL] [Abstract][Full Text] [Related]
12. Persisting right-sided chylothorax in a patient with chronic lymphocytic leukemia: a case report.
Scholz GA; Sirbu H; Semrau S; Anders K; Mackensen A; Spriewald BM
J Med Case Rep; 2011 Oct; 5():492. PubMed ID: 21968097
[TBL] [Abstract][Full Text] [Related]
13. Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL).
Wright N; Voshtina E; George G; Singavi A; Field J
Int J Hematol; 2019 Dec; 110(6):751-755. PubMed ID: 31494832
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
15. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
[TBL] [Abstract][Full Text] [Related]
16. Tumor lysis syndrome in a chronic lymphocytic leukemia patient with pleural effusion after oral fludarabine and cyclophosphamide therapy.
Nakazawa H; Nishina S; Mimura Y; Kawakami T; Senoo Y; Sakai K; Nakazawa K; Kitano K
Int J Hematol; 2014 Jun; 99(6):782-5. PubMed ID: 24584911
[TBL] [Abstract][Full Text] [Related]
17. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Fraser G; Cramer P; Demirkan F; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Pavlovsky MA; Karlsson C; Hallek M; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Chanan-Khan A
Leukemia; 2019 Apr; 33(4):969-980. PubMed ID: 30315239
[TBL] [Abstract][Full Text] [Related]
18. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
[TBL] [Abstract][Full Text] [Related]
19. Hemorrhagic pleural effusion as a complication of chronic lymphocytic leukemia.
Zeidman A; Yarmolovsky A; Djaldetti M; Mittelman M
Haematologia (Budap); 1995; 26(3):173-5. PubMed ID: 7797147
[TBL] [Abstract][Full Text] [Related]
20. ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib.
Syrykh C; Ysebaert L; Péricart S; Evrard SM; Meggetto F; Kanoun S; Brousset P; Laurent C
Virchows Arch; 2021 Apr; 478(4):779-783. PubMed ID: 33011863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
